About: Giuseppe Saglio

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Giuseppe Saglio Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Italian clinical immunologist, hematologist and researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) 연구원 (ko) ricercatore (it) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) वैज्ञानिक (hi) باحت (ary) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtues (sq) Italian clinical immunologist, hematologist and researcher (en) włoski immunolog kliniczny i hematolog (pl)
rdfs:label	Giuseppe Saglio (en) Giuseppe Saglio (es) Giuseppe Saglio (it) Giuseppe Saglio (nl) Giuseppe Saglio (pl) Giuseppe Saglio (sl) Giuseppe Saglio (ast)
skos:prefLabel	Giuseppe Saglio (en) Giuseppe Saglio (es) Giuseppe Saglio (it) Giuseppe Saglio (nl) Giuseppe Saglio (pl) Giuseppe Saglio (sl) Giuseppe Saglio (ast)
name	Giuseppe Saglio (en) Giuseppe Saglio (es) Giuseppe Saglio (it) Giuseppe Saglio (nl) Giuseppe Saglio (pl) Giuseppe Saglio (sl) Giuseppe Saglio (ast)
Scopus author ID	wds:Q53342434-58664CD6-2280-4F23-A47A-AF78BC322E3E
Scopus author ID	7102391260
given name	wds:Q53342434-C448BEA2-BFFC-43C7-8AC0-51B01626465F
given name	Giuseppe
instance of	wds:Q53342434-3A2DC4E7-99D0-42C8-858D-CF01D677ADDA
instance of	Homo sapiens
occupation	wds:Q53342434-DD701498-A2C6-4C2C-9F74-4CF7A0FFB6E2
Parsifal cluster ID	wds:Q53342434-C8040BAD-39E0-4365-8987-3352D7837303
place of birth	wds:Q53342434-3d185886-4a3a-83cc-f81a-648a815e9918
sex or gender	wds:Q53342434-3D0C6CC2-9B19-4C19-8A5F-194835F42996
VIAF ID	wds:Q53342434-0E79598C-0759-42E7-922D-35B5CE476FB1
date of birth	wds:Q53342434-a57a6d27-4f02-ab1b-ade6-28569236bbdd
family name	wds:q53342434-341ee359-4ac7-d67a-bfec-b49e4ac195b2
WorldCat Identities ID (superseded)	wds:Q53342434-08639831-015F-432A-AE19-FE48FD986902
VIAF ID	http://viaf.org/viaf/27200687
occupation	researcher
Parsifal cluster ID	669503
place of birth	Turin
sex or gender	male
VIAF ID	27200687
date of birth	1950-05-17 00:00:00Z (xsd:dateTime)
family name	Saglio
WorldCat Identities ID (superseded)	lccn-n94075564
ORCID iD	wds:Q53342434-E08FA006-EE4D-445F-B31A-105D36D77BBC
ORCID iD	https://orcid.org/0000-0002-1046-3514
ORCID iD	0000-0002-1046-3514
Iris-AperTO author ID	wds:Q53342434-D63E85A7-8077-4FAD-A136-7A9D47E505B8
Iris-AperTO author ID	16080
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q53342434
is author of	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia Chronic myeloid leukemia: state of the art in 2012. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial Two novel mutations in the tmprss6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients. WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. Molecular pathways: BCR-ABL. PML targeting eradicates quiescent leukaemia-initiating cells Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results Preferential clustering of chromosomal breakpoints in Burkitt's lymphomas and L3 type acute lymphoblastic leukemias with a t(8;14) translocation Fetal diagnosis of beta-thalassaemia by DNA analysis in Italy Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia Significance of a new type of human fetal hemoglobin carrying a replacement isoleucine replaced by threonine at position 75 )E 19) of the gamma chain Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software